
Waters Corporation WAT
$ 332.95
1.31%
Quarterly report 2025-Q3
added 11-04-2025
Waters Corporation General and Administrative Expenses 2011-2026 | WAT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Waters Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 M | 180 M | 658 M | 627 M | 554 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 658 M | 173 M | 438 M |
Quarterly General and Administrative Expenses Waters Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 214 M | 201 M | 175 M | - | 169 M | 173 M | 175 M | - | 187 M | 187 M | 182 M | - | 164 M | - | 157 M | 173 M | 153 M | 158 M | 143 M | 153 M | 135 M | 117 M | 148 M | 141 M | 126 M | 133 M | 134 M | 143 M | 127 M | 137 M | 130 M | 148 M | 135 M | 130 M | 131 M | 130 M | 124 M | 130 M | 129 M | 129 M | 125 M | 123 M | 120 M | 132 M | 122 M | 132 M | 127 M | 131 M | 121 M | 123 M | 119 M | 122 M | 115 M | 123 M | 117 M | 126 M | 121 M | 125 M | 117 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 214 M | 115 M | 141 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Trinity Biotech plc
TRIB
|
24.7 M | $ 0.73 | -1.86 % | $ 61.9 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 29.0 | -3.07 % | $ 316 M | ||
|
Brainsway Ltd.
BWAY
|
5.78 M | $ 23.87 | -0.13 % | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.14 | -2.16 % | $ 1.45 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
9.06 M | $ 104.95 | -1.72 % | $ 4.14 B | ||
|
Co-Diagnostics
CODX
|
14.3 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
7.76 B | $ 210.56 | -0.33 % | $ 154 B | ||
|
Castle Biosciences
CSTL
|
200 M | $ 29.41 | -6.17 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 202.21 | -0.11 % | $ 22.4 B | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
1.29 B | $ 73.08 | 1.11 % | $ 28.5 B | ||
|
DarioHealth Corp.
DRIO
|
18.1 M | $ 11.75 | 2.8 % | $ 333 M | ||
|
CareDx, Inc
CDNA
|
118 M | $ 18.83 | -5.23 % | $ 1.01 B | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Illumina
ILMN
|
1.09 B | $ 117.53 | -2.06 % | $ 18.7 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 23.18 | -0.39 % | $ 701 M | ||
|
Exact Sciences Corporation
EXAS
|
889 M | $ 103.45 | 0.15 % | $ 19.5 B | ||
|
Lantheus Holdings
LNTH
|
194 M | $ 74.31 | 1.54 % | $ 5.14 B | ||
|
Guardant Health
GH
|
211 M | $ 103.36 | -2.84 % | $ 13 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 99.61 | 1.22 % | $ 8.22 B | ||
|
Interpace Biosciences
IDXG
|
9.49 M | $ 1.85 | 2.78 % | $ 8.12 M | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 169.68 | 3.11 % | $ 8.41 B | ||
|
IDEXX Laboratories
IDXX
|
442 M | $ 635.6 | 0.77 % | $ 52.4 B | ||
|
IQVIA Holdings
IQV
|
2 B | $ 166.19 | -1.87 % | $ 28.6 B | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 31.19 | 0.73 % | $ 20 B | ||
|
Biodesix
BDSX
|
80.5 M | $ 13.26 | 4.0 % | $ 1.72 B | ||
|
Quidel Corporation
QDEL
|
66.6 M | $ 22.47 | -4.85 % | $ 947 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 283.38 | 0.32 % | $ 23.8 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.17 | -2.25 % | $ 4.98 M | ||
|
Bioventus
BVS
|
304 M | $ 8.57 | -0.06 % | $ 537 M | ||
|
Medpace Holdings
MEDP
|
198 M | $ 452.99 | 1.47 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
National Research Corporation
NRC
|
46.6 M | $ 13.65 | 9.64 % | $ 335 M | ||
|
Mettler-Toledo International
MTD
|
998 M | $ 1 378.44 | 0.14 % | $ 28.4 B |